Mexico’s Emili Zoe Calls Attention to RSHO-X™
August 11th, 2016
News, Top Story
Cannabis has been long demonized by the United States where it remains a Schedule I Controlled Substance. With its significant foreign policy reach, these sentiments have been pushed onto neighboring countries like Mexico. Former President Filipe Caldron’s War on Drugs led to at least 60,000 Mexican deaths between 2006 and 2012, despite illicit earnings of between $13.6 billion to $49.4 billion ending up in the pockets of criminal enterprises.
The good news is that the tides are turning with the legalization of medical and recreational marijuana in both the United States (on a state level) and Canada (nationwide). On February 1, 2016, Mexico’s government made a surprising shift in its stance on cannabis after the Health Department (COFEPRIS) found that Medical Marijuana, Inc.’s (OTC: MJNA) RSHO-X™ contained “non-detectable” THC and was approved for import from the United States.
The decision to approve the import of RSHO-X™ came after the families of Maria Paula, 5, and Alina Maldonado Montes de Oca, 11, lobbied the government to import the cannabidiol (CBD) oil to treat medical conditions that couldn’t be treated with other existing therapies. Since then, Medical Marijuana, Inc. established its HempMeds® Mexico subsidiary and initiated an educational tour to highlight the many potential benefits of cannabidiol (CBD).
Emili Zoe’s Case
The government’s shift has expanded access to RSHO-X™ to a number of other individuals suffering from medical conditions that don’t respond to other therapeutics.
For example, Emili Zoe began experiencing chronic seizures when she was two-months old due to a genetic disorder. In their search for a treatment, Emili’s parents discovered Medical Marijuana, Inc.’s RSHO-X™ cannabidiol oil through the Por Grace Foundation. The therapy immediately stopped the seizures and restored her quality of life, while highlighting the potential for CBD-based therapeutics in treating a variety of conditions.
Watch a video highlighting Emili Zoe’s story below.
“A Hope for Emili” held an informational conference in mid-July to discuss the potential benefits associated with medical cannabis. At the event, various specialists were present to discuss these benefits alongside HempMeds® personnel. Emili’s grandfather noted that at least 24 families with similar conditions have reached out for more information, which prompted the conference to address these questions and potential for RSHO-X™.
The importation of RSHO-X™ marks the first step in a long march towards legalization of medical and, potentially, recreational marijuana throughout Mexico.
“[We believe] that full legalization of all cannabis products may soon be a reality within Mexico,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “Regardless of any near-term additional regulatory decisions, our Company is honored to be the first distributor to Mexico of cannabis-based products to families that have been awarded government import permits. We applaud this first step forward by the regulators to allow our RSHO-X™ product and the great efforts of Mexican lawmakers for acting on behalf of the welfare of the Mexican people.”
Mexico’s Supreme Court already ruled that marijuana for recreational use could be decriminalized in November 2015. In April, Mexican President Pena Nieto proposed legalizing medical marijuana and easing limits for personal use of the drug. He indicated that he would be sending a bill to Congress to increase the amount users can legally carry from the current five grams to 28 grams – or one ounce.
“We, Mexicans, know all too well the range and the defects of prohibitionist and punitive policies, and of the so-called war on drugs that has prevailed for 40 years,” said President Nieto in a statement at the time. “Fortunately, a new consensus is gradually emerging worldwide in favor of reforming drug policies. A growing number of countries are strenuously combatting criminals, but instead of criminalizing consumers, they offer them alternatives.”
Medical Marijuana, Inc.’s RSHO-X™ became the first cannabinoid-based treatment approved for import to Mexico for the treatment of various medical conditions. With the tides turning on legalization, the company is well positioned to capitalize on the liberalization of drug policies and to help improve the lives of millions of patients. In fact, Mexico’s cannabis industry is estimated to be roughly the same size as California’s enormous industry.
Investors interested in the medical cannabis and cannabinoid space may want to take a closer look at Medical Marijuana, Inc. given these trends.
For more information, visit the company’s website at www.medicalmarijuanainc.com.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.